Takeda Pharmaceutical Co Ltd
Close on Nov 20, 2026Market cap $75.03BP/E –Yield –
Takeda Pharmaceutical Adjusted Net Debt to Adjusted EBITDA Leverage Ratio by Quarter
Adjusted Net Debt to Adjusted EBITDA Leverage Ratio (×)
Takeda Pharmaceutical Adjusted Net Debt to Adjusted EBITDA Leverage Ratio: 2.50× in Q2 FY27, down 7.4% from a year earlier. That is the lowest of the 11 quarters on record here.
Where the Q2 FY27 figure comes from
“|| Adjusted Net Debt/Adjusted EBITDA ratio | 2.5x | Proceeds from issuance of bonds | 526.1 | —”
Source: SEC EDGAR Filing (exhibit991_102926.htm) ↗
Reported in Form 6-K Exhibit 99.1 Quarterly Financial Appendix.
quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Adjusted Net Debt to Adjusted EBITDA Leverage Ratio (×) | Year on year | Source |
|---|---|---|---|---|
| Q2 FY27CQ3 2026 | Sep 30, 2026 | 2.50 | -7.4% | SEC EDGAR Filing (exhibit991_102926.htm) ↗ |
| Q1 FY27CQ2 2026 | Jun 30, 2026 | 2.70 | -6.9% | SEC EDGAR Filing (exhibit991_073026.htm) ↗ |
| Q4 FY26CQ1 2026 | Mar 31, 2026 | 2.60 | -7.1% | SEC EDGAR Filing (exhibit991_051326.htm) ↗ |
| Q3 FY26CQ4 2025 | Dec 31, 2025 | 2.70 | 0.0% | SEC EDGAR Filing (exhibit991_012926.htm) ↗ |
| Q2 FY26CQ3 2025 | Sep 30, 2025 | 2.70 | -6.9% | SEC EDGAR Filing (exhibit991_103025.htm) ↗ |
| Q1 FY26CQ2 2025 | Jun 30, 2025 | 2.90 | -6.5% | SEC EDGAR Filing (exhibit991_073025.htm) ↗ |
| Q4 FY25CQ1 2025 | Mar 31, 2025 | 2.80 | -9.7% | SEC EDGAR Filing (exhibit991_050825.htm) ↗ |
| Q3 FY25CQ4 2024 | Dec 31, 2024 | 2.70 | – | SEC EDGAR Filing (exhibit991_013025.htm) ↗ |
| Q2 FY25CQ3 2024 | Sep 30, 2024 | 2.90 | – | SEC EDGAR Filing (exhibit991_103124.htm) ↗ |
| Q1 FY25CQ2 2024 | Jun 30, 2024 | 3.10 | – | SEC EDGAR Filing (exhibit991_073124.htm) ↗ |
| Q4 FY24CQ1 2024 | Mar 31, 2024 | 3.10 | – | SEC EDGAR Filing (exhibit991_073124.htm) ↗ |
Breakdown
What makes up adjusted Net Debt to Adjusted EBITDA Leverage Ratio
- Book Value of Bonds and Loans (Gross Debt, IFRS)-4,575.60 · Q2 FY27
- Net Debt (IFRS Book Value Basis)-4,157.10 · Q2 FY27
- Hybrid Subordinated Debt 50% Equity Credit Adjustment250.00 · Q2 FY27
- Adjusted Gross Debt (After Hybrid Equity Credit & FX Adjustment)-4,352.60 · Q2 FY27
- Adjusted Net Debt-3,917.90 · Q2 FY27
- Adjusted EBITDA (Last Twelve Months / LTM)1,540.30 · Q2 FY27
- Consolidated EBITDA (Quarterly & Annual)247.20 · Q2 FY27
- Consolidated Adjusted EBITDA (Quarterly & Annual)426.60 · Q2 FY27
Cite this data
StockData. (2026). Takeda Pharmaceutical Adjusted Net Debt to Adjusted EBITDA Leverage Ratio (×), quarterly Q4 FY24–Q2 FY27 [Data set]. Compiled from Takeda Pharmaceutical SEC filings and investor materials. https://stockdatahq.com/stocks/tak/kpis/sec-leverage-ratio
See every metric in the Takeda Pharmaceutical KPI table. Data updated Nov 10, 2026.
See a number that looks wrong?